Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition
Lung Cancer
Sex
Male or Female
Age
18+ years
Healthy participants
No
Visit ClinicalTrials.gov for more information

Eligibility criteria

Study overview

The proposed study seeks to address a critical gap in the management of lorlatinib-induced metabolic derangements, particularly rapid weight gain, which can adversely affect treatment adherence, dosing and ultimately patient outcomes. In this study patients with non-small cell lung cancer (NSCLC) receiving lorlatinib treatment will receive tirzepatide, a dual GIP/GLP-1 receptor agonist with demonstrated efficacy in weight reduction and metabolic improvement. This study seeks to evaluate its potential to mitigate side effects while preserving the therapeutic efficacy of lorlatinib.

View locations for this study

Find the closest location, your results will be shown below
Find the closest location
    Miles
    0500

    Nearest Locations found

    1 site found

    University of Chicago Medicine Comprehensive Cancer Center

    Chicago, Illinois, United States, 60637
    Site Info
    • Recruitment Status
    • Site details
    • Study Contact
    • Clinical Trials ID

    Study Locations

    View locations for this studyFind the closest location, your results will be shown belowFind the closest location